[Company Contact China Biologic Products Reports Results for the Year 2011 Beijing, China, March 12, 2012 – China Biologic Products, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), today reported its financial results for the year ended December 31, 2011. Financial highlights for the year 2011] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): March 12, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or former address, if changed]

[FORM 10-K (Mark One) December 31, 2011 Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 18th Floor, Jialong International Building, 19 Chaoyang Park Road (+86) 10-6598-3111 Title of each class Name of each exchange on which registered Common Stock, par value $0.0001 per share NASDAQ Global] [The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-171069) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated March 12, 2012, with respect to the consolidated balance sheets of China Biologic Products, Inc. and subsidiaries as of December 31, 2011] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of We consent to the use of our report dated March 23, 2010, except for the effects on the consolidated financial statements of the restatement described in Note 2, as to which the date is March 31, 2011, with respect to the consolidated balance sheets of China Biologic] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Yu-Yun Tristan Kuo, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th (Principal Financial and Accounting Officer)]

[Company Contact FOR RELEASE ON NOVEMBER 7, 2011 AT 4:20 p.m. EST (New York) China Biologic Reports Third Quarter 2011 Results TAI'AN, Shandong Province, China, November 7, 2011 – China Biologic Products, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), today reported its financial results for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 7, 2011 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or former address, if changed]